Psychosocial and Financial Burden of Therapy in USA Patients with Pulmonary Arterial Hypertension.

Autor:	Helgeson SA; Department of Pulmonary Medicine, Mayo Clinic, Jacksonville, FL 32224, USA., Menon D; Department of Pulmonary and Critical Care Medicine, Tufts Medical Center, Boston, MA 02111, USA., Helmi H; Department of Emergency Medicine, University of Florida, Jacksonville, FL 32224, USA., Vadlamudi C; Department of Pulmonary Medicine, Mayo Clinic, Jacksonville, FL 32224, USA., Moss JE; Department of Pulmonary Medicine, Mayo Clinic, Jacksonville, FL 32224, USA., Zeiger TK; Department of Pulmonary Medicine, Mayo Clinic, Jacksonville, FL 32224, USA., Burger CD; Department of Pulmonary Medicine, Mayo Clinic, Jacksonville, FL 32224, USA.
Jazyk:	angličtina
Zdroj:	Diseases (Basel, Switzerland) [Diseases] 2020 Jun 13; Vol. 8 (2). Date of Electronic Publication: 2020 Jun 13.
DOI:	10.3390/diseases8020022
Abstrakt:	A bstract: Pulmonary arterial hypertension (PAH) is a devastating disease with significant morbidity and mortality. There are many psychosocial and financial implications of this disease; however, little is known how this affects the treatment of PAH patients. A questionnaire-based prospective cohort study was performed on 106 PAH patients from a Pulmonary Hypertension Center and the Pulmonary Hypertension Association national conference in 2018. The demographic, treatment, psychosocial, employment, financial impact on treatment data was obtained. The majority of patients had cardiopulmonary symptoms despite treatment. The symptoms affected their social and work lives, with about one in three applying for disability because of their PAH. The majority of PAH patients had insurance coverage, but still noted a significant financial burden of the disease, with nearly a half who needed financial assistance to pay for their PAH medications. Thirty (28.3%; 95% CI, 20.6-37.5%) patients mentioned they changed their medication regimen, with some skipping doses outright (28 [26.4%; 95% CI, 19-35.6%]) in order to save money. PAH continues to cause significant psychosocial and financial burden on patients despite advances in medications. This impact ranged from dissatisfaction with quality of life, to unemployment, to altering their medication regimen to save money. Competing Interests: The authors declare no conflict of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu